OGI Organigram Global Inc.
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vap…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 Organigram (OGI) Q3 2026 Earnings Call Transcript Revenue jumped 49% to $105.8 million on Sanity acquisition. | ||
Weekly Roundup on the Cannabis Sector & Psychedelic Sector Key Takeaways; Cannabis Sector Curaleaf Holdings Announced Intention to Launch a Hostile Takeover Bid to Acquire Aurora Cannabis Organigram Posted Record Quarter as Sanity Group Acquisition Fueled Global Expansion Key Takeaways; Psychedelic Sector Optimi Health Set Up US$100 Million Equity Facility to Support Growth Definium Therapeutics’ Phase 3 Trial Delivered Strong Results for DT120 in […] | ||
 Organigram Global Inc. Q3 2026 Earnings Call Summary Moby summary of Organigram Global Inc.'s Q3 2026 earnings call | ||
Organigram Global Inc (OGI) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA ... International expansion drives 49% revenue surge and record profitability, with full-year guidance raised above $350 million. | ||
 OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates OrganiGram (OGI) delivered earnings and revenue surprises of -400.00% and +12.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Organigram Global Q3 Earnings Call Highlights Organigram Global (NASDAQ:OGI) reported record third-quarter fiscal 2026 revenue and adjusted EBITDA, aided by the consolidation of Germany-based Sanity Group and improving performance in several Canadian cannabis categories. Net revenue rose 49% year over year to C$105.8 million, while adjusted EB | ||